ACADIA PHARMACEUTICALS INC (ACAD)
US0042251084 - Common Stock
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
3 Pharma Stocks to Sell in April Before They Crash & Burn
Discover three pharma stocks to sell in April, facing challenges and signaling potential for significant downside.
Oversold Conditions For Acadia Pharmaceuticals (ACAD)
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 Pharma Stocks to Sell in March Before They Crash & Burn
Discover top pharma stocks to sell in March before they plummet. Learn why ACAD, AMLX and WST are on the list for urgent sell-off decisions.
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
Acadia Pharmaceuticals Becomes Oversold (ACAD)
Why Are Airline Stocks Down Today?
Airline stocks are down on Tuesday as investors deal with several bits of bad news for the industry on Tuesday!
Why Is Acadia Pharmaceuticals (ACAD) Stock Down 18% Today?
Acadia Pharmaceuticals stock is falling on Tuesday as investors in ACAD react to its failed Phase 3 clinical trial of pimavanserin.
Acadia Hits 11-Month Low After Outsized Placebo Effect Torpedoes Schizophrenia Study
The company says it doesn't plan to further develop Nuplazid in clinical testing.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out this morning as we get into all of the biggest winners and losers for Tuesday!
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("ACADIA" or the "Company") (NASDAQ: ACAD). Such...
Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
3 Stock Winners That Are Up 1,000% or More in 2024
Dig deep enough, and find a story hot enough, and you can uncover potential stock winners up 1,000%. Here are three.
3 Stock Winners That Are Up 1,000% or More in 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Dig deep enough and find a story hot enough, and you can uncover potential stoc...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("ACADIA" or the "Company") (NASDAQ: ACAD). Such...
Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024
Noteworthy Wednesday Option Activity: CYRX, ABR, ACAD
Acadia Stock Dives As Unexpected Seasonality Rocks Its Most High-Profile Launch
CEO Steve Davis said there was a lot of pent-up demand when Daybue first launched last year.
Acadia Pharma GAAP EPS of $0.28 misses by $0.02, revenue of $231.04M beats by $7.24M (NASDAQ:ACAD)
ACAD's Q4 GAAP EPS misses by $0.02, but revenue beats expectations.
